Publications, Pharmaceutical

Advancing Nose to Brain Drug Delivery: Intranasal Administration of Insulin

Intranasal delivery of drugs has gained significant attention in recent years, especially for targeting brain-related conditions such as Alzheimer’s disease. This innovative approach bypasses the blood-brain barrier, offering a more efficient method for delivering therapeutic agents directly to the central nervous system. Among the most promising treatments being explored is intranasal insulin, which has shown potential in improving memory, functional ability, and cerebrospinal fluid biomarker profiles in Alzheimer’s patients. A recent study titled “First Biodistribution Study of [68Ga]Ga-NOTA-Insulin Following Intranasal Administration in Adult Vervet Monkeys” investigates the biodistribution of insulin in the brain after intranasal administration using a novel radiotracer and delivery system.

Download Nose To Brain Publication
Author(s): KIran Kumar Solingapuram Sai, Department of Radiology, Wake Forest School of Medicine Jennifer M. Erichsen, Department of Internal Medicine, Division of Gerontology and Geriatric Medicine, Wake Forest School of Medicine Krishna K. Gollapelli, Department of Radiology, Wake Forest School of Medicine Ivan Krizan, Department of Radiology, Wake Forest School of Medicine Mack Miller, Department of Radiology, Wake Forest School of Medicine Avinash Bansode, Department of Radiology, Wake Forest School of Medicine Matthew J. Jorgensen, Department of Pathology, Division of Comparative Medicine, Wake Forest School of Medicine Thomas Register, Department of Pathology, Division of Comparative Medicine, Wake Forest School of Medicine Charles Cazzola, Aptar Pharma Reenal Gandhi, Aptar Pharma Julie Suman, Aptar Pharma Suzanne Craft, Department of Internal Medicine, Division of Gerontology and Geriatric Medicine, Wake Forest School of Medicine
2 Oct 2024

Background
Intranasal insulin is under exploration as a treatment for Alzheimer’s disease due to its potential to improve cognitive function and modify disease progression. This study aims to further investigate the biodistribution and brain uptake of intranasal insulin in a preclinical setting, specifically in vervet monkeys, which are considered relevant animal models for such research.

The delivery method used in this study, the Aptar Pharma’s Cartridge Pump System (CPS), is key to achieving reliable and targeted intranasal drug delivery. One of the challenges in the field of intranasal delivery is ensuring that the therapeutic agent reaches the brain in sufficient concentrations to be effective, without exposing the rest of the body to excessive doses. The biodistribution study utilized a novel radiotracer, Gallium 68-labeled NOTA-conjugated insulin ([68Ga]Ga-NOTA-insulin), to trace the movement of insulin throughout the body, focusing on its accumulation in the brain.

 

Study Objective
The primary objective of this study was to demonstrate the successful delivery of insulin to the brain using Aptar Pharma’s CPS intranasal drug delivery system in healthy adult vervet monkeys. The researchers also aimed to establish the safety of this method by evaluating vital signs, blood glucose levels, and overall radiation exposure during the procedure.

 

Methods
To visualize and measure the brain’s uptake of insulin after intranasal administration, the researchers developed [68Ga]Ga-NOTA-insulin, a PET radiotracer. Positron Emission Tomography (PET) combined with CT scans was employed to monitor the distribution of the insulin throughout the body and assess brain regional activity in real-time.

The study involved anesthetized adult vervet monkeys, which were given intranasal doses of [68Ga]Ga-NOTA-insulin through Aptar Pharma’s CPS device. PET/CT imaging was then conducted to track the radiotracer and determine which brain regions showed uptake. Additionally, safety assessments, such as monitoring vital signs and measuring glucose levels, were conducted to ensure that the insulin administration did not induce adverse effects.

 

Results
The study demonstrated that intranasal delivery of [68Ga]Ga-NOTA-insulin via the Aptar Pharma’s CPS drug delivery system resulted in successful insulin uptake in various brain regions. Specifically, the researchers observed significant activity in the amygdala, putamen, hypothalamus, hippocampus, and choroid plexus—all key areas associated with memory, emotional processing, and neurodegenerative diseases like Alzheimer’s.

The whole-body dosimetry revealed that no organ was exposed to more than 2.5 mSv of radioactivity, confirming the safety of the procedure. The monkeys’ vital signs remained stable throughout the study, and blood glucose levels were unaffected, indicating that the intranasal administration of [68Ga]Ga-NOTA-insulin did not disrupt systemic glucose metabolism.

Moreover, the data gathered from the vervet monkeys were used to estimate the absorbed dose of [68Ga]Ga-NOTA-insulin in humans. The study concluded that the maximum safe dose for human administration is 185 MBq, which is critical information for future clinical trials.

As intranasal insulin continues to be explored as a treatment for Alzheimer’s, the data from this research will be instrumental in guiding the development of clinical protocols and ensuring that the right dose reaches the brain effectively. This preclinical biodistribution study in vervet monkeys sets a strong foundation for future investigations into the therapeutic potential of intranasal insulin in humans, particularly in addressing neurodegenerative diseases.

 

Implications for Future Research
The successful targeting of insulin to the brain using the Aptar Pharma’s CPS nasal drug delivery system opens new avenues for the treatment of Alzheimer’s disease through intranasal drug delivery. Future research will focus on translating these findings to human studies, with the potential to significantly impact the management and treatment of Alzheimer’s Disease.

 

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

8 Oct 2024

Understanding PBPK Modeling in OINDPs: Insights from Will Ganley

Publications, Pharmaceutical, Market Insights, Product Solutions

Read More
2 Oct 2024

Advancing Nose to Brain Drug Delivery: Intranasal Administration of Insulin

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
30 Sep 2024

Cyclosporine – A Micellar Nasal Spray: A Promising Antiviral Solution Against S...

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
24 Apr 2024

Advancing OINDP Clinical Trials with Speed and Efficiency: Strategies for Success

Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
1 2 3 26
Back To Top